Last edition
News about "KRAS G12D-targeted protein degrader"
Astellas Advances Setidegrasib Into Phase 3 Trial for NSCLC
Astellas has dosed the first patient in a Phase 3 study evaluating setidegrasib against docetaxel in patients with KRAS G12D-mutated NSCLC.
KRAS G12D-targeted Protein Degrader | 25/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members